No Data
Ferment Launches $20M Studio Fund to Accelerate Biotech Solutions Across Vital Industries
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $10
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $6
Ginkgo Bioworks Price Target Lowered to $6 From $7 at BTIG
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Ginkgo Bioworks's Restructuring Starting to Bear Fruit, Says TD Cowen
QMengColdJoke : still a fraud after 40 to 1 reverse split.
TechTrek Invest OP QMengColdJoke : That's a very emotional response. Where is the evidence? Have you notified the SEC of your findings?
What's the fraud?
Share price falling isn't fraudulent.
COVID profits fell considerably - again losing revenue streams.is not fraudulent.
Core buisiness is growing.
Good AI development.
Reducing cost.
Ginkgo has good long term.potential.